TCR2 Therapeutics falls on bigger-than-expected Q1 loss
11/05/2023 18:09
** Shares of drug developer TCR2 Therapeutics Inc TCRR.O
down 1.01% at $1.96
** Co posts bigger-than-expected Q1 loss of $1.03 per share
vs analysts' est for loss of $0.68 per share - Refinitiv data
** Co ended the quarter with $110.3 mln in cash, cash
equivalents and investments
** TCRR stock up ~100% YTD
(Reporting by Rupali Chaudhary in Bengaluru)
((Rupali.chaudhary@thomsonreuters.com))
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview